Browse

Depressive Symptoms and Brain Metabolite Alterations in Subjects at Ultra-high Risk for Psychosis: A Preliminary Study

DC Field Value Language
dc.contributor.authorByun, Min Soo-
dc.contributor.authorChoi, Jung-Seok-
dc.contributor.authorYoo, So Young-
dc.contributor.authorKang, Do-Hyung-
dc.contributor.authorJang, Dong Pyo-
dc.contributor.authorJung, Myung Hun-
dc.contributor.authorLee, Jong-Min-
dc.contributor.authorKwon, Jun Soo-
dc.contributor.authorJang, Joon Hwan-
dc.contributor.authorJung, Wi Hoon-
dc.contributor.authorChoi, Chi-Hoon-
dc.date.accessioned2012-07-05T00:47:18Z-
dc.date.available2012-07-05T00:47:18Z-
dc.date.issued2009-12-
dc.identifier.citationPSYCHIATRY INVESTIGATION; Vol.6 4; 264-271ko_KR
dc.identifier.issn1738-3684-
dc.identifier.urihttps://hdl.handle.net/10371/78526-
dc.description.abstractObjective Recent neuroimaging studies have suggested that brain changes occur in subjects at Ultra-high risk (UHR) for psychosis while experiencing prodromal symptoms, among which depression may increase the risk of developing a psychotic disorder. The goal of this study is to examine brain metabolite levels in the anterior cingulate cortex, the left dorsolateral prefrontal cortex and the left thalamus in Subjects at UHR for psychosis and to compare brain metabolite levels between the UHR subjects with comorbid major depressive disorder and healthy controls. Methods Proton magnetic resonance spectroscopy was used to examine brain metabolite levels. Twenty UHR subjects and 20 age- and intelligence quotient (IQ)-matched healthy controls were included in this study. Results Overall, no significant differences were observed in any metabolite between the UHR and healthy control group. However, UHR subjects with major depressive disorder showed significantly higher myo-inositol (Ins) levels in the left thalamus, compared to the healthy control. Conclusion Our results demonstrate that increased thalamic Ins level is associated with prodromal depressive symptoms. Further longitudinal follow-up Studies with larger UHR sample sizes are required to investigate the function of Ins concentrations as a biomarker Of Vulnerability to psychosis. Psychiatry Invest 2009;6:264-271ko_KR
dc.description.sponsorshipThis paper was supported by a grant (M10644020003-08N4402-
00310) from the Cognitive Neuroscience Program of the Korean Ministry
of Science and Technology of the Republic of Korea.
ko_KR
dc.language.isoenko_KR
dc.publisherKOREAN NEUROPSYCHIATRIC ASSOCko_KR
dc.subjectDepressionko_KR
dc.subjectMagnetic resonance spectroscopyko_KR
dc.subjectUltra-high riskko_KR
dc.subjectSchizophreniako_KR
dc.titleDepressive Symptoms and Brain Metabolite Alterations in Subjects at Ultra-high Risk for Psychosis: A Preliminary Studyko_KR
dc.typeArticleko_KR
dc.contributor.AlternativeAuthor변민수-
dc.contributor.AlternativeAuthor최정석-
dc.contributor.AlternativeAuthor유소영-
dc.contributor.AlternativeAuthor강도형-
dc.contributor.AlternativeAuthor최치훈-
dc.contributor.AlternativeAuthor장동표-
dc.contributor.AlternativeAuthor정이훈-
dc.contributor.AlternativeAuthor정명훈-
dc.contributor.AlternativeAuthor장준환-
dc.contributor.AlternativeAuthor이종민-
dc.contributor.AlternativeAuthor권준수-
dc.identifier.doi10.4306/pi.2009.6.4.264-
dc.citation.journaltitlePSYCHIATRY INVESTIGATION-
dc.description.citedreferenceYoo SY, 2009, SCHIZOPHR RES, V111, P86, DOI 10.1016/j.schres.2009.03.036-
dc.description.citedreferenceWood SJ, 2009, NEUROBIOL DIS, V33, P354, DOI 10.1016/j.nbd.2008.11.018-
dc.description.citedreferenceSoares DP, 2009, CLIN RADIOL, V64, P12, DOI 10.1016/j.crad.2008.07.002-
dc.description.citedreferenceAydin K, 2008, BIOL PSYCHIAT, V64, P750, DOI 10.1016/j.biopsych.2008.04.007-
dc.description.citedreferenceChoi JS, 2008, PROG NEURO-PSYCHOPH, V32, P1326, DOI 10.1016/j.pnpbp.2008.04.011-
dc.description.citedreferenceWhalley HC, 2008, J AFFECT DISORDERS, V109, P99, DOI 10.1016/j.jad.2007.11.009-
dc.description.citedreferenceYoung KA, 2008, BRIT J PSYCHIAT, V192, P285, DOI 10.1192/bjp.bp.107.039180-
dc.description.citedreferenceGreicius MD, 2007, BIOL PSYCHIAT, V62, P429, DOI 10.1016/j.biopsych.2006.09.020-
dc.description.citedreferenceBorgwardt SJ, 2007, BIOL PSYCHIAT, V61, P1148, DOI 10.1016/j.biopsych.2006.08.009-
dc.description.citedreferenceJessen F, 2006, SCHIZOPHR RES, V87, P81, DOI 10.1016/j.schres.2006.06.011-
dc.description.citedreferenceVelakoulis D, 2006, ARCH GEN PSYCHIAT, V63, P139-
dc.description.citedreferenceYung AR, 2005, AUST NZ J PSYCHIAT, V39, P964-
dc.description.citedreferenceCaetano SC, 2005, NEUROSCI LETT, V384, P321, DOI 10.1016/j.neulet.2005.04.099-
dc.description.citedreferenceKim H, 2005, HUM PSYCHOPHARM CLIN, V20, P309, DOI 10.1002/hup.693-
dc.description.citedreferenceJang DP, 2005, MAGNET RESON MED, V53, P708, DOI 10.1002/mrm.20387-
dc.description.citedreferenceSilverstone PH, 2005, BIPOLAR DISORD, V7, P1-
dc.description.citedreferenceJohnstone EC, 2005, BRIT J PSYCHIAT, V186, P18-
dc.description.citedreferenceNeumeister A, 2004, ARCH GEN PSYCHIAT, V61, P765-
dc.description.citedreferenceTheberge J, 2004, PSYCHIAT RES-NEUROIM, V131, P107, DOI 10.1016/j.pscychresns.2004.04.002-
dc.description.citedreferenceYoung KA, 2004, AM J PSYCHIAT, V161, P1270-
dc.description.citedreferenceTibbo P, 2004, AM J PSYCHIAT, V161, P1116-
dc.description.citedreferenceYung AR, 2004, SCHIZOPHR RES, V67, P131, DOI 10.1016/S0920-9964(03)00192-0-
dc.description.citedreferenceSmith EA, 2003, BIOL PSYCHIAT, V54, P1399, DOI 10.1016/S0006-3223(03)00474-8-
dc.description.citedreferenceVythilingam M, 2003, BIOL PSYCHIAT, V54, P744, DOI 10.1016/S0006-3223(03)01908-X-
dc.description.citedreferenceGruber S, 2003, INVEST RADIOL, V38, P403, DOI 10.1097/01.rli.0000073446.43445.20-
dc.description.citedreferenceYucel M, 2003, BRIT J PSYCHIAT, V182, P518-
dc.description.citedreferenceYoon U, 2003, ANN BIOMED ENG, V31, P441, DOI 10.1114/1.1557973-
dc.description.citedreferenceWood SJ, 2003, SCHIZOPHRENIA BULL, V29, P831-
dc.description.citedreferenceFarchione TR, 2002, BIOL PSYCHIAT, V52, P86-
dc.description.citedreferenceMalhi GS, 2002, AUST NZ J PSYCHIAT, V36, P31-
dc.description.citedreferenceAuer DP, 2001, SCHIZOPHR RES, V52, P87-
dc.description.citedreferenceDrevets WC, 2000, BIOL PSYCHIAT, V48, P813-
dc.description.citedreferenceHafner H, 1999, ACTA PSYCHIAT SCAND, V100, P105-
dc.description.citedreferenceFrey R, 1998, J PSYCHIAT RES, V32, P411-
dc.description.citedreferenceFIRST MB, 1996, STRUCTURED CLIN INTE-
dc.description.citedreferencePROVENCHER SW, 1993, MAGNET RESON MED, V30, P672-
dc.description.citedreferenceMICHAELIS T, 1993, RADIOLOGY, V187, P219-
dc.description.citedreferenceDAGER SR, 1992, NEUROPSYCHOPHARMACOL, V6, P249-
dc.description.citedreferenceYUM TH, 1992, MANUAL KOREAN WECHSL-
dc.description.citedreferenceKAY SR, 1987, SCHIZOPHRENIA BULL, V13, P261-
dc.description.citedreferenceLUKOFF D, 1986, SCHIZOPHRENIA BULL, V12, P578-
dc.description.citedreferenceHAMILTON M, 1967, BRIT J SOC CLIN PSYC, V6, P278-
dc.description.citedreferenceHAMILTON M, 1959, BRIT J MED PSYCHOL, V32, P50-
dc.description.tc1-
Appears in Collections:
College of Medicine/School of Medicine (의과대학/대학원)Psychiatry (정신과학전공)Journal Papers (저널논문_정신과학전공)
Files in This Item:
  • mendeley

Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse